Updates on DNA methylation modifiers in acute myeloid leukemia.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Acute myeloid leukemia (AML) is a prevalent adult cancer.
• Standard chemotherapy for AML has significant adverse events, particularly in elderly patients.
• Alternative therapies are crucial for patients intolerant to conventional treatment.

Purpose of the Study:

• To review the efficacy and safety of hypomethylating agents (HMA) and isocitrate dehydrogenase (IDH) inhibitors in AML treatment.
• To highlight recent therapeutic advancements for specific AML patient groups.
• To discuss the evolving landscape of AML therapy.

Main Methods:

• Review of first- and second-generation hypomethylating agents (HMA).
• Review of isocitrate dehydrogenase (IDH) inhibitors.
• Analysis of clinical data on HMA and IDH inhibitor efficacy and safety in AML.

Main Results:

• HMA (azacitidine, decitabine) are effective and safe for AML patients ineligible for standard chemotherapy.
• Combination of HMA with venetoclax is FDA-approved for older/unfit AML patients.
• IDH inhibitors show promise in relapsed/refractory AML with IDH mutations and have FDA approval.

Conclusions:

• HMA and IDH inhibitors represent significant advancements in AML treatment for specific patient populations.
• These newer agents offer improved safety and efficacy profiles compared to traditional chemotherapy.
• Ongoing research is expected to yield further therapeutic options for acute myeloid leukemia.